JPRN-UMIN000003402已完成2 期
Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS3) - Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS3)
Miyagi HBPCOG0 个研究点目标入组 35 人开始时间: 2010年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) pulmonary fibrosis or interstitial pneumonitis 2) tumor other than ductal carcinoma 3) distant metastasis 4) R2 resection 5) prior anti-cnacer therapy 6) pregnancy 7) under 18 years old
研究者
相似试验
已完成
2 期
Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS2+2)resectable pancreatic cancerJPRN-UMIN000009070EXTSURG35
已完成
2 期
Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 for resectable pancreatic carcinomaresectable pancreatic cancerJPRN-UMIN000004148Study group of preoperative therapy for pancreatic cancer (Prep)80
招募中
2 期
The phase 2 study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with biological borderline resectable pancreatic cancer.Pancreatic ductal adenocarcinomaJPRN-UMIN000030717Department of gastrointestinal Surgery, Hiroshima University Hospital50
招募中
2 期
The phase 2 study of neoadjuvant chemotherapy of GAS for biological borderline resectable pancreatic cancer.Biological borderline resectable pancreatic cancerJPRN-jRCTs061180009emura Kenichiro50
已完成
不适用
Feasibility study of adjuvant chemotherapy with gemcitabine and cisplatin for completely resected NSCLCCompletely resected NSCLC (stage IB - IIIA including multiple N2)JPRN-UMIN000005256Kumamoto University Hospital25